Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Noven Therapeutics
With
Noven Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder characterized by 3 main symptoms: inattention, hyperactivity and impulsivity. This study will assess the safety and tolerability of SPD485 while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.
Age
6–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must have a primary diagnosis of ADHD
Subject must be adequately controlled on a stable dose of one of the following medications for a 30 day period: Ritalin LA(r), Concerta(r), or Metadate DC(r), not to exceed 54 mg per day
Females of childbearing potential must have a negative serum beta Human Chorionic Gonadotropin pregnancy test
You may not be if
A history of mental retardation that would indicate that the subject is not functioning at an age appropriate level intellectually
A recent history of suspected substance abuse or dependence disorder
Subject is taking Strattera
Clinical signs and symptoms of skin irritation or hyper/hypopigmentation at the potential application sites
